Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：159頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 11
Therapeutics Development 12
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 12
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 13
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 14
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 17
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 22
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25
Osiris Therapeutics, Inc. 25
Gamida Cell Ltd. 26
Nanotherapeutics, Inc. 27
CEL-SCI Corporation 28
Aeolus Pharmaceuticals, Inc. 29
Cleveland BioLabs, Inc. 30
Soligenix, Inc. 31
NeoStem, Inc. 32
Pluristem Therapeutics Inc. 33
Cellerant Therapeutics, Inc. 34
Humanetics Corporation 35
Meabco A/S 36
ActoKine Therapeutics 37
ProCertus BioPharm Inc. 38
Onconova Therapeutics, Inc. 39
Bolder Biotechnology, Inc. 40
Biothera, Inc. 41
ImmuneRegen BioSciences, Inc. 42
Terapio Corporation 43
Neumedicines Inc. 44
HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG 45
Midway Pharmaceuticals, Inc. 46
Stealth Peptides Inc. 47
Galera Therapeutics LLC 48
RxBio, Inc. 49
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Target 51
Assessment by Mechanism of Action 54
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
remestemcel-L - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
entolimod - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
minocycline - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NMIL-121 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BIO-300 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SGX-201 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GC-003 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Leukocyte Interleukin Injection - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
recilisib sodium - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
GC-4403 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NanoDTPA - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
SGX-202 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Homspera - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
rusalatide acetate - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
BP-C2 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
romyelocel L - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
MTP-131 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
BBT-045 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MDY-1001 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Radiogardase (Prussian Blue insoluble capsules) - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
JP4-039 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
PLX-BMP - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
GC-4419 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Rx-100 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Stem Cell Therapy For Radiation Exposure - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
BIO-700 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
BIO-800 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
CLT-009 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
PrC-210 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
SY-303A - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
1Y-41 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
AK-1 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Adipose-Derived Stromal Cell Replacement Therapy - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Hemokine - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Imprime WGP - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
prussian blue insoluble - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
BBT-015 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
BBT-018 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
BBT-007 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
AEOL-10171 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Small Molecules for Radiation Toxicity - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
TPO-7630 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates 120
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 148
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 149
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 150
Featured News & Press Releases 150
Feb 03, 2014: U.S. National Institutes of Health to Commence New Study of Pluristem's PLX Cells for Acute Radiation Syndrome Treatment 150
Jan 23, 2014: Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA 150
Jan 23, 2014: Cleveland BioLabs Provides Update on Barda Development Proposal 151
Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 151
Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 152
Dec 05, 2013: Aeolus Files Application for New Patent on AEOL 10150 153
Oct 29, 2013: Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation 153
Sep 25, 2013: Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield in GI ARS 155
Sep 17, 2013: BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome 155
Sep 09, 2013: CEL-SCI's Manufacturing and Laboratory Operations Deemed Compliant with GMP Requirements Following Audit by European Union Qualified Person for a Second Time 156
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2014 12
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2014 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Osiris Therapeutics, Inc., H1 2014 25
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Gamida Cell Ltd., H1 2014 26
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nanotherapeutics, Inc., H1 2014 27
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by CEL-SCI Corporation, H1 2014 28
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 29
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H1 2014 30
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H1 2014 31
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by NeoStem, Inc., H1 2014 32
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H1 2014 33
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H1 2014 34
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H1 2014 35
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2014 36
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ActoKine Therapeutics, H1 2014 37
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H1 2014 38
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H1 2014 39
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H1 2014 40
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Biothera, Inc., H1 2014 41
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ImmuneRegen BioSciences, Inc., H1 2014 42
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H1 2014 43
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H1 2014 44
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG, H1 2014 45
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Midway Pharmaceuticals, Inc., H1 2014 46
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stealth Peptides Inc., H1 2014 47
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics LLC, H1 2014 48
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H1 2014 49
Assessment by Monotherapy Products, H1 2014 50
Number of Products by Stage and Target, H1 2014 53
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 58
Number of Products by Stage and Molecule Type, H1 2014 60
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H1 2014 120
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2014 148
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2014 149
List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2014 12
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Products, H1 2014 21
Assessment by Monotherapy Products, H1 2014 50
Number of Products by Top 10 Target, H1 2014 51
Number of Products by Stage and Top 10 Target, H1 2014 52
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 57
Number of Products by Stage and Top 10 Route of Administration, H1 2014 58
Number of Products by Top 10 Molecule Type, H1 2014 59
Number of Products by Stage and Top 10 Molecule Type, H1 2014 60
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 11
Therapeutics Development 12
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 12
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 13
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 14
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 17
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 22
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25
Osiris Therapeutics, Inc. 25
Gamida Cell Ltd. 26
Nanotherapeutics, Inc. 27
CEL-SCI Corporation 28
Aeolus Pharmaceuticals, Inc. 29
Cleveland BioLabs, Inc. 30
Soligenix, Inc. 31
NeoStem, Inc. 32
Pluristem Therapeutics Inc. 33
Cellerant Therapeutics, Inc. 34
Humanetics Corporation 35
Meabco A/S 36
ActoKine Therapeutics 37
ProCertus BioPharm Inc. 38
Onconova Therapeutics, Inc. 39
Bolder Biotechnology, Inc. 40
Biothera, Inc. 41
ImmuneRegen BioSciences, Inc. 42
Terapio Corporation 43
Neumedicines Inc. 44
HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG 45
Midway Pharmaceuticals, Inc. 46
Stealth Peptides Inc. 47
Galera Therapeutics LLC 48
RxBio, Inc. 49
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Target 51
Assessment by Mechanism of Action 54
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
remestemcel-L - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
entolimod - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
minocycline - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NMIL-121 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BIO-300 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SGX-201 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GC-003 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Leukocyte Interleukin Injection - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
recilisib sodium - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
GC-4403 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NanoDTPA - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
SGX-202 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Homspera - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
rusalatide acetate - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
BP-C2 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
romyelocel L - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
MTP-131 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
BBT-045 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MDY-1001 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Radiogardase (Prussian Blue insoluble capsules) - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
JP4-039 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
PLX-BMP - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
GC-4419 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Rx-100 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Stem Cell Therapy For Radiation Exposure - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
BIO-700 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
BIO-800 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
CLT-009 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
PrC-210 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
SY-303A - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
1Y-41 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
AK-1 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Adipose-Derived Stromal Cell Replacement Therapy - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Hemokine - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Imprime WGP - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
prussian blue insoluble - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
BBT-015 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
BBT-018 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
BBT-007 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
AEOL-10171 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Small Molecules for Radiation Toxicity - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
TPO-7630 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates 120
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 148
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 149
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 150
Featured News & Press Releases 150
Feb 03, 2014: U.S. National Institutes of Health to Commence New Study of Pluristem's PLX Cells for Acute Radiation Syndrome Treatment 150
Jan 23, 2014: Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA 150
Jan 23, 2014: Cleveland BioLabs Provides Update on Barda Development Proposal 151
Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 151
Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 152
Dec 05, 2013: Aeolus Files Application for New Patent on AEOL 10150 153
Oct 29, 2013: Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation 153
Sep 25, 2013: Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield in GI ARS 155
Sep 17, 2013: BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome 155
Sep 09, 2013: CEL-SCI's Manufacturing and Laboratory Operations Deemed Compliant with GMP Requirements Following Audit by European Union Qualified Person for a Second Time 156
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2014 12
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2014 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Osiris Therapeutics, Inc., H1 2014 25
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Gamida Cell Ltd., H1 2014 26
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nanotherapeutics, Inc., H1 2014 27
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by CEL-SCI Corporation, H1 2014 28
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 29
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H1 2014 30
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H1 2014 31
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by NeoStem, Inc., H1 2014 32
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H1 2014 33
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H1 2014 34
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H1 2014 35
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2014 36
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ActoKine Therapeutics, H1 2014 37
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H1 2014 38
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H1 2014 39
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H1 2014 40
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Biothera, Inc., H1 2014 41
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ImmuneRegen BioSciences, Inc., H1 2014 42
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H1 2014 43
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H1 2014 44
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG, H1 2014 45
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Midway Pharmaceuticals, Inc., H1 2014 46
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stealth Peptides Inc., H1 2014 47
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics LLC, H1 2014 48
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H1 2014 49
Assessment by Monotherapy Products, H1 2014 50
Number of Products by Stage and Target, H1 2014 53
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 58
Number of Products by Stage and Molecule Type, H1 2014 60
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H1 2014 120
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2014 148
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2014 149
List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2014 12
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Products, H1 2014 21
Assessment by Monotherapy Products, H1 2014 50
Number of Products by Top 10 Target, H1 2014 51
Number of Products by Stage and Top 10 Target, H1 2014 52
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 57
Number of Products by Stage and Top 10 Route of Administration, H1 2014 58
Number of Products by Top 10 Molecule Type, H1 2014 59
Number of Products by Stage and Top 10 Molecule Type, H1 2014 60
